Steve Elms - 10 Jun 2021 Form 4 Insider Report for Zosano Pharma Corp

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2021, 20:38:43 UTC
Prior SEC filing: 10 Jun 2021
Next SEC filing: 09 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Steven Lo, Attorney-in-Fact for Steve Elms

Key filing fact

Steve Elms filed Form 4 for Zosano Pharma Corp on 14 Jun 2021.

Key facts

This page summarizes Steve Elms's Form 4 filing for Zosano Pharma Corp.
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2021, 20:38.

Change

Previous filing in this sequence was filed on 10 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZSAN transaction

Common Stock

Award

Transaction value: $0
Shares: +15,000
Change %: +200%
Price: $0.000000
Shares after: 22,500
Date: 10 Jun 2021
Ownership: Direct
Footnotes: F1

ZSAN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,718,226
Date: 10 Jun 2021
Ownership: (2)
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZSAN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 10 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $0.9318
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units which vest in a single installment on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date.

Footnote F2

Represents shares directly held by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Footnote F3

The option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date.